8,845$
1,67%
Echtzeit-Aktienkurs Amneal Pharmaceuticals
Bid:
Ask:
Echtzeit-Chart der Amneal Pharmaceuticals Aktie
Börsenkurse Amneal Pharmaceuticals
| Echtzeit Euro | - | - | - | - | 8,075€ | 2,22% |
| Lang & Schwarz | - | - | - | - | 8,100€ | 0,93% |
| New York | - | - | - | - | 8,845$ | 1,67% |
| Nasdaq | - | - | - | - | 6,070$ | 0,00% |
| gettex | - | - | - | - | 8,100€ | 0,62% |
| Echtzeit USD | - | - | - | - | 8,841$ | 1,50% |
| Tradegate | - | - | - | - | 8,100€ | 0,00% |
| USA | - | - | - | - | 8,840$ | 1,49% |
| Börse Stuttgart | - | - | - | - | 8,000€ | 1,27% |
| Börse Frankfurt | - | - | - | - | 8,100€ | 3,18% |
Fundamentaldaten der Amneal Pharmaceuticals Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 2,39 Mrd. | -40,27 Mio. | -83,99 Mio. | -0,48 | - | - | 1,13 |
| 2022 [USD] | 2,21 Mrd. | -248,13 Mio. | -129,99 Mio. | -0,86 | - | - | 0,61 |
| 2021 [USD] | 2,09 Mrd. | 31,37 Mio. | 10,62 Mio. | 0,07 | - | 126,36 | 0,63 |
| 2020 [USD] | 1,99 Mrd. | -35,78 Mio. | 91,06 Mio. | 0,61 | - | 14,45 | 0,66 |
| 2019 [USD] | 1,63 Mrd. | -220,24 Mio. | -361,92 Mio. | -2,74 | - | - | 0,80 |
| 2018 [USD] | 1,66 Mrd. | -202,72 Mio. | -20,92 Mio. | -0,16 | - | - | 0,68 |
| 2017 [USD] | - | - | - | 0,00 | - | - | - |
| 2016 [USD] | 824,43 Mio. | -576,33 Mio. | -472,03 Mio. | -6,63 | - | - | 0,79 |
| 2015 [USD] | 860,47 Mio. | 59,37 Mio. | 39,00 Mio. | 0,54 | - | 16,38 | 0,75 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Amneal Pharmaceuticals Aktie
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.